Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
ASCO GI 2026 | San Francisco, CA
Jan 8 - 10, 2026
Poster
Phase 1/2 Study of ARV-806, a PROTAC KRAS G12D Degrader, in KRAS G12D-mutated Advanced Solid Tumors, including Pancreatic CancerSABCS 2025 | San Antonio, TX
Dec 9 - 12, 2025
Poster
Circulating Tumor DNA Biomarker Analyses of a Phase 1/2 Study Evaluating Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in ER+/HER2- Advanced Breast CancerSABCS 2025 | San Antonio, TX
Dec 9 - 12, 2025
Poster
Real-world Prevalence of ESR1 Mutations Among Patients With ER+/HER2- Metastatic Breast Cancer After First-line Treatment With Endocrine Therapy and/or a CDK4/6 InhibitorSABCS 2025 | San Antonio, TX
Dec 9 - 12, 2025
Poster
Subgroup Analyses of VERITAC-2: A Phase 3 Trial of Vepdegestrant, a PROTAC ER Degrader, vs Fulvestrant in ER+/HER2- Advanced Breast CancerASH 2025 | Orlando, FL
Dec 6 - 9, 2025
Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With the CD20×CD3 Bispecific Glofitamab in a Preclinical Model of HGBCLSFN 2025 | San Diego, CA
Nov 15 - 19, 2025
Poster
ARV-102, a PROTAC LRRK2 Degrader, Modulates Pathways Associated With Parkinson’s Disease and Progressive Supranuclear Palsy: Proteomic Analyses of CSF From Non-human Primates and Healthy VolunteersISPOR-EU 2025 | Glasgow, UK
Nov 9 - 12, 2025
Poster
Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast CancerISPOR-EU 2025 | Glasgow, UK
Nov 9 - 12, 2025
Poster
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility DataSITC 2025 | National Harbor, MD
Nov 5 - 9, 2025